These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28766115)

  • 41. Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
.
    Eisen C; Lulic Z; Palacios-Moreno JM; Adalig B; Hennig M; Cortes V; Gilg F; Kostev K
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):37-49. PubMed ID: 31670653
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 5 alpha-reductase inhibitors: what's new?
    Foley CL; Kirby RS
    Curr Opin Urol; 2003 Jan; 13(1):31-7. PubMed ID: 12490813
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
    Dolder CR
    Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A review of combination therapy in patients with benign prostatic hyperplasia.
    McVary KT
    Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs.
    Angrimani DSR; Silvestrini GR; Brito MM; Abreu RA; Almeida LL; Vannucchi CI
    Theriogenology; 2018 Jul; 114():103-108. PubMed ID: 29605575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.
    Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z
    J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Change in International Prostate Symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea.
    Lee JY; Lee SH; Kim SJ; Kim CS; Lee HM; Kim CI; Chung BH
    Urology; 2011 Jan; 77(1):171-6. PubMed ID: 20691464
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
    Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
    J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort.
    Dekalo S; McArthur E; Campbell J; Ordon M; Power N; Welk B
    Urol Oncol; 2023 Jan; 41(1):50.e11-50.e17. PubMed ID: 36319553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.
    Ingimarsson JP; Isaksson HJ; Sigbjarnarson HP; Gudmundsson J; Geirsson G
    Scand J Urol; 2014 Feb; 48(1):73-8. PubMed ID: 23924152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data.
    Sandhu JS; Te AE
    Curr Urol Rep; 2004 Aug; 5(4):274-9. PubMed ID: 15260927
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Combination drug therapy in patients with BPH].
    Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA
    Urologiia; 2018 Mar; (1):101-105. PubMed ID: 29634142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
    Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
    PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hormonal manipulation of benign prostatic hyperplasia.
    Rick FG; Saadat SH; Szalontay L; Block NL; Kazzazi A; Djavan B; Schally AV
    Curr Opin Urol; 2013 Jan; 23(1):17-24. PubMed ID: 23202285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience.
    Guevara-Cuellar CA; Parody-Rúa E; Garcia-Perdomo HA; Arenas-Duque A
    Value Health Reg Issues; 2018 Dec; 17():174-182. PubMed ID: 30415110
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.
    Liang JA; Sun LM; Lin MC; Chang SN; Sung FC; Muo CH; Kao CH
    Oncologist; 2012; 17(7):986-91. PubMed ID: 22723508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dutasteride for the treatment of prostate-related conditions.
    Slater S; Dumas C; Bubley G
    Expert Opin Drug Saf; 2012 Mar; 11(2):325-30. PubMed ID: 22316171
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study.
    Kravchick S; Cytron S; Mamonov A; Peled R; Linov L
    Urology; 2009 Jun; 73(6):1274-8. PubMed ID: 19375786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.